Nieuws en video's - ZEALAND PHARMA A/S ZLDPF

Company announcement - No. 29 / 2024 Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL Copenhagen, Denmark, June 6, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) today announced that an embargoed abstract of positive results from Boehringer Ingelheim’s Phase 2 trial of survodutide (BI 456906) in metabolic dysfunction-associated steatohepatitis (MASH) due to be presented at the European Association of the Study of...

Press release – No. 6 / 2024 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency Copenhagen, Denmark, May 31, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued...

Press release – No. 5 / 2024 Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024 Copenhagen, Denmark, May 29, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Adam Steensberg, President and CEO, will participate in fireside chats at the following healthcare investor conferences in June: Jefferies Global Healthcare...

Company announcement – No. 28 / 2024 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark, 29 May 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 24 May 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: As of 22 May...

Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean weight loss of up to 4.3% after 12 weeks with low doses of dapiglutide treatment Dapiglutide was assessed to be well-tolerated Tolerability profile observed suggests doses investigated were at the lower end of the therapeutic range Much higher doses of dapiglutide are being investigated in the...

Company announcement - No. 26 / 2024 Zealand Pharma Announces Financial Results for the First Quarter of 2024 Strong performance in the first quarter of 2024 paving the way for important data read-outs across differentiated obesity assets in the second quarter. Strong topline results announced in Boehringer Ingelheim Phase 2 clinical trial for survodutide in MASH PDUFA date for glepaglutide in SBS set by US FDA for December 22, 2024 PDUFA date for dasiglucagon in CHI for up to three weeks of...

Company announcement – No. 25 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, May 12, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities...

Press Release – No. 4 / 2024 Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results Copenhagen, Denmark, May 9, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 16, 2024, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter of 2024. Presenting...

Correction to Company announcement – No. 23 / 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has a correction to company announcement No. 23 /2024, April 19, 2024 - regarding transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their...

Company announcement – No. 23 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related...

Company announcement – No. 22 / 2024 Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the implementation of long-term incentive programs (the “LTIP”) for Zealand's...

Company announcement – No. 21 / 2024 Total number of shares and voting rights in Zealand Pharma at March 31, 2024 Copenhagen, Denmark, March 31, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a...

Company announcement – No. 20 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, March 26, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related...

Company announcement – No. 19 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, March 26, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 32,808 divided into 32,808 new shares with a nominal value of DKK 1 each....

Company announcement – No. 18 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 21 March 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 21 March 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: As...

Company announcement – No. 17 / 2024 Zealand Pharma's Annual General Meeting 2024 Copenhagen, March 20, 2024 - Today, Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR no. 20 04 50 78), held its Annual General Meeting of 2024 as a partly electronic and partly physical general meeting (hybrid meeting). At the meeting, all proposals presented to the General Meeting were adopted. The General Meeting acknowledged the management's report on Zealand's activities in the past financial year and...

Company announcement – No. 16 / 2024 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark, 19 March 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 18 March 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: As of 15...

Company announcement – No. 15 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, March 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related...

Company announcement – No. 14 / 2024 New Employee Elected Directors to the Board of Zealand Pharma A/S Copenhagen, Denmark, March 13, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78). The employees of Zealand Pharma A/S have elected the following employee representatives and alternates for the Company’s Board of Directors: Employee representatives: Frederik Beck (re-elected) Anneline Nansen (re-elected) Ludovic Otterbein (newly elected) Adam Nygaard (newly...

Company announcement – No. 13 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, March 8, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related...